LianBio Development

LianBio was a cross-border biotechnology company focused on bringing innovative medicines to patients in China and other major Asian markets. Founded in 2019 by Perceptive Advisors, the company established a robust pipeline of late-stage assets through strategic in-licensing agreements with global biopharmaceutical companies. Its portfolio spanned multiple therapeutic areas, including cardiovascular, oncology, ophthalmology, and inflammatory diseases. In February 2024, following the sale of its lead asset mavacamten to Bristol Myers Squibb, LianBio announced a formal plan to wind down its operations, sell its remaining assets, and delist from the Nasdaq. The company is currently in the process of liquidating its remaining programs and returning value to shareholders.